Dihydroquinoline Carbamate Derivatives as "Bio-oxidizable" Prodrugs for Brain Delivery of Acetylcholinesterase Inhibitors: [¹¹C] Radiosynthesis and Biological Evaluation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  ACS Chemical Neuroscience

• Publication date

  2015-02-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/cn5003539PMID 25695305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Meserine, a Novel Carbamate AChE Inhibitor, Ameliorates Scopolamine‐Induced Dementia and Alleviates Amyloidogenesis of APP/PS1 Transgenic Mice

  2014cited by this paper
• Distribution of Intravenously Administered Acetylcholinesterase Inhibitor and Acetylcholinesterase Activity in the Adrenal Gland: 11C-Donepezil PET Study in the Normal Rat

  2014cited by this paper
• An update on drug treatment options of Alzheimer's disease.

  2014cited by this paper
• Tau protein kinases: involvement in Alzheimer's disease.

  2013cited by this paper
• Tau protein and tau aggregation inhibitors.

  2010cited by this paper
• Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system.

  2010cited by this paper
• Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.

  2010cited by this paper
• Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors

  2010cited by this paper
• Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease.

  2010cited by this paper
• Alzheimer's disease: from pathology to therapeutic approaches.

  2009cited by this paper
• Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery.

  2009cited by this paper
• Rational design of central selective acetylcholinesterase inhibitors by means of a "bio-oxidisable prodrug" strategy.

  2009cited by this paper
• The chemistry of Alzheimer's disease.

  2009cited by this paper
• Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

  2008cited by this paper
• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  2006cited by this paper
• Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.

  2004cited by this paper
• Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium.

  2004cited by this paper
• Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

  2003cited by this paper
• Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease.

  2002cited by this paper
• Targeting drugs to the brain by redox chemical delivery systems

  2000cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

  1996cited by this paper
• The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro

  1989cited by this paper
• A new and rapid colorimetric determination of acetylcholinesterase activity.

  1961cited by this paper

• Intermittent supplementation with Akkermansia muciniphila and galactooligosaccharides modulates Alzheimer’s disease progression, gut microbiota, and colon short-chain fatty acid profiles in mice

  2025cites this paper
• Implication of Central β2 Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease

  2025cites this paper
• Prodrugs and their activation mechanisms for brain drug delivery

  2025cites this paper
• Carbamate as a potential anti‐Alzheimer's pharmacophore: A review

  2023cites this paper
• Advances in prodrug design for Alzheimer’s disease: the state of the art

  2022cites this paper
• Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.

  2022cites this paper
• An insight into prodrug strategy for the treatment of Alzheimer’s disease

  2022cites this paper
• Acid‐Base Magnetic Silica Heterogeneous Catalyst for Green Aldol and Aza‐Michael Reactions

  2021cites this paper
• Prodrug strategy for enhanced therapy of central nervous system disease.

  2021cites this paper
• Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective.

  2021cites this paper
• Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.

  2020cites this paper
• The chemistry of labeling heterocycles with carbon-11 or fluorine-18 for biomedical imaging

  2020cites this paper
• Covalent Inhibition Mechanism of Antidiabetic Drugs—Vildagliptin vs Saxagliptin

  2019cites this paper
• The Structural Hybrids of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease: A Review

  2019cites this paper
• Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors.

  2019cites this paper
• Chemical Delivery System of MIBG to the Central Nervous System: Synthesis, 11C-Radiosynthesis, and in Vivo Evaluation.

  2019cites this paper
• Overview of Recent Strategic Advances in Medicinal Chemistry.

  2019cites this paper
• Profiling donepezil template into multipotent hybrids with antioxidant properties

  2018cites this paper
• Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine "bio-oxidizable" prodrugs: Synthesis, biological evaluation and structure-activity relationship.

  2018cites this paper
• Dihydroquinoline Carbamate DQS1-02 as a Prodrug of a Potent Acetylcholinesterase Inhibitor for Alzheimer’s Disease Therapy: Multigram-Scale Synthesis, Mechanism Investigations, in Vitro Safety Pharmacology, and Preliminary in Vivo Toxicology Profile

  2018cites this paper
• Access to Highly Enantioenriched Donepezil-like 1,4-Dihydropyridines as Promising Anti-Alzheimer Prodrug Candidates via Enantioselective Tsuji Allylation and Organocatalytic Aza-Ene-Type Domino Reactions.

  2018cites this paper
• Rational design of carbamate-based dual binding site and central AChE inhibitors by a "biooxidisable" prodrug approach: Synthesis, in vitro evaluation and docking studies.

  2018cites this paper
• Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.

  2017cites this paper
• Delivering FLT to the Central Nervous System by Means of a Promising Targeting System: Synthesis, [11C]Radiosynthesis, and in Vivo Evaluation.

  2017cites this paper
• Medicinal Chemistry and Brain Drug Penetrance

  2017cites this paper
• Synthesis and in vitro evaluation of novel N-cycloalkylcarbamates as potential cholinesterase inhibitors

  2017cites this paper
• Synthesis, characterization and in vitro evaluation of substituted N-(2-phenylcyclopropyl)carbamates as acetyl- and butyrylcholinesterase inhibitors

  2016cites this paper
• Enzyme-catalyzed asymmetric domino aza-Michael/aldol reaction for the synthesis of 1,2-dihydroquinolines using pepsin from porcine gastric mucosa

  2016cites this paper
• Palladium-Catalyzed Carbonylation of (Hetero)Aryl, Alkenyl and Allyl Halides by Means of N-Hydroxysuccinimidyl Formate as CO Surrogate.

  2015cites this paper